Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Nat Cardiovasc Res. 2022 Aug 29;1(9):817–829. doi: 10.1038/s44161-022-00117-6

Fig. 8 |. Decreased ceramides and elevated LPLs in failing hearts.

Fig. 8 |

a, Volcano plot of differences in ceramide abundance in cardiac tissue, comparing nonfailing with failing samples. b, Relative mRNA expression of ceramide synthesis enzymes. SPTLC1 FDR = 0.000282; SPTLC2 FDR = 0.0228; CERS2 FDR = 0.0281; CERS5 FDR = 0.00122; CERS6 FDR = 0.000149; DEGS1 FDR = 5.70 × 10−5. c, Volcano plot of differences in PL abundance in cardiac tissue, comparing nonfailing with failing samples. d, Relative mRNA expression of PL synthesis enzymes. CHPT1 FDR = 1.17 × 10−5; EPT1 FDR = 5.41 × 10−7; ETNK1 FDR = 0.0467; PCYT2 FDR = 0.0308. e, Volcano plot of differences in LPL abundance in cardiac tissue, comparing nonfailing with failing samples. f, Relative mRNA expression of LPL synthesis enzymes. LPCAT3 FDR = 4.53 × 10−5; PLA2G4C FDR = 0.0159. The dotted line represents the threshold of statistical significance (FDR corrected). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. P values were determined by FDR-corrected, two-tailed Student’s t-test.